Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma

Abstract

ObjectiveTo identify biomarkers associated with the effectiveness of ipilimumab plus nivolumab against advanced metastatic renal cell carcinoma.MethodsWe retrospectively analyzed the data of 75 patients treated with ipilimumab plus nivolumab at seven hospitals between August 2018 and April 2021. Prognostic biomarkers were assessed prior to initiating treatment with ipilimumab plus nivolumab. Median overall survival and progression‐free survival were examined using the Kaplan–Meier method. Univariate and multivariate analyses were performed to identify predictors of disease progression. The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factors most important for predicting disease progression were determined using classification and regression tree analysis.ResultsMedian overall survival and progression‐free survival were longer in the intermediate IMDC risk group than in the poor IMDC risk group (overall: not reached vs. 18.3 months; progression‐free: not reached vs. 13.5 months). The multivariate analysis identified poor IMDC risk as a risk factor for disease progression (hazard ratio 2.61, 95% confidence interval: 1.05–6.51). Based on the results of the classification and regression tree analysis, the cohort was divided into non‐anemia, anemia + neutro‐Low, and anemia + neutro‐High groups. Median overall survival and progression‐free survival were longer in the non‐anemia and anemia + neutro‐Low groups than in the anemia + neutro‐High group (overall: not reached vs. 29.3 months vs. 4.3 months: progression‐free: not reached vs. 29.0 months vs. 3.9 months).ConclusionHemoglobin and neutrophil levels may represent crucial biomarkers for predicting the effectiveness of ipilimumab plus nivolumab therapy in patients with renal cell carcinoma.